Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Payables (2016 - 2025)

Amphastar Pharmaceuticals has reported Payables over the past 13 years, most recently at $32.6 million for Q4 2025.

  • Quarterly results put Payables at $32.6 million for Q4 2025, down 79.25% from a year ago — trailing twelve months through Dec 2025 was $32.6 million (down 79.25% YoY), and the annual figure for FY2025 was $32.6 million, down 79.25%.
  • Payables for Q4 2025 was $32.6 million at Amphastar Pharmaceuticals, down from $190.8 million in the prior quarter.
  • Over the last five years, Payables for AMPH hit a ceiling of $190.8 million in Q3 2025 and a floor of $18.8 million in Q2 2023.
  • Median Payables over the past 5 years was $35.3 million (2024), compared with a mean of $67.2 million.
  • Biggest five-year swings in Payables: tumbled 80.72% in 2023 and later skyrocketed 459.86% in 2025.
  • Amphastar Pharmaceuticals' Payables stood at $89.5 million in 2021, then tumbled by 77.11% to $20.5 million in 2022, then surged by 355.42% to $93.4 million in 2023, then skyrocketed by 68.22% to $157.1 million in 2024, then tumbled by 79.25% to $32.6 million in 2025.
  • The last three reported values for Payables were $32.6 million (Q4 2025), $190.8 million (Q3 2025), and $166.6 million (Q2 2025) per Business Quant data.